Communiqués Intellia Therapeutics, Inc.

Actions

NTLA

US45826J1051

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 16/07/2024			Varia. 5j.	Varia. 1 janv.
27,35 ^USD	+5,15 %		+22,87 %	-10,30 %

26/06	Intellia Therapeutics nomme Edward Dulac directeur financier	MT
26/06	Intellia Therapeutics, Inc. annonce des changements au sein de son équipe dirigeante	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Kuehn Law Encourages Investors of Intellia Therapeutics, Inc. to Contact Law Firm	02/07	PR
Intellia Therapeutics Announces CFO Transition	26/06	AQ
Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform	25/06	AQ
Intellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024	17/06	AQ
Intellia Therapeutics Names Brian Goff to its Board of Directors	14/06	AQ
Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema	03/06	AQ
Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)	02/06	AQ
Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress	09/05	AQ
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates	02/05	AQ
Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024	29/04	AQ
Intellia Therapeutics : Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine - Form 8-K	15/04	PU
Intellia Therapeutics : Termination of Material Agreement - Form 8-K	22/03	PU
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy	18/03	AQ
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress	22/02	AQ
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis	15/02	BU
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates	15/02	AQ
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates	14/02	AQ
AvenCell Announces First Patient Dosed in a Phase IA Study with lead product candidate AVC-201, a Novel Allogeneic CD123-Directed Switchable CAR-T Investigational Therapy	07/02	AQ
Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine	31/01	AQ
Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones	04/01	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Intellia Therapeutics, Inc.

Actions

NTLA

US45826J1051

Communiqués

Filtres